Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?

Expert Rev Mol Diagn. 2019 Jul;19(7):553-558. doi: 10.1080/14737159.2019.1622414. Epub 2019 Jun 10.

Authors

Daniel S K Liu^{1

2}, Mireia Mato Prado², Elisa Giovannetti^{3

4}, Long R Jiao¹, Jonathan Krell², Adam E Frampton^{1

2}

Affiliations

¹ a HPB Surgical Unit, Dept. of Surgery & Cancer , Imperial College, Hammersmith Hospital campus , London , UK.
² b Division of Cancer, Dept. of Surgery & Cancer , Imperial College , London , UK.
³ c Department of Medical Oncology, Cancer Center Amsterdam , Amsterdam UMC, VU University Medical Center (VUmc), 1081 HV , , Amsterdam , The Netherlands.
⁴ d Fondazione Pisana per la Scienza , 56017 , Pisa , Italy.

PMID: 31159604
DOI: 10.1080/14737159.2019.1622414

No abstract available

Keywords: Circulating tumor DNA (ctDNA); KRAS; PDAC; biomarker; exosomes; pancreatic ductal adenocarcinoma; survival.

Publication types

Editorial
Letter

MeSH terms

Biomarkers, Tumor*
Carcinoma, Pancreatic Ductal / blood
Carcinoma, Pancreatic Ductal / diagnosis*
Carcinoma, Pancreatic Ductal / genetics
Circulating Tumor DNA*
Exosomes* / genetics
Exosomes* / metabolism
Humans
Liquid Biopsy
Neoplastic Cells, Circulating*
Pancreatic Neoplasms / blood
Pancreatic Neoplasms / diagnosis*
Pancreatic Neoplasms / genetics

Substances

Biomarkers, Tumor
Circulating Tumor DNA